Fate Therapeutics Inc. (FATE)
Fate Therapeutics Statistics
Share Statistics
Fate Therapeutics has 114.6M shares outstanding. The number of shares has increased by 0.67% in one year.
| Shares Outstanding | 114.6M |
| Shares Change (YoY) | 0.67% |
| Shares Change (QoQ) | 0.62% |
| Owned by Institutions (%) | 86.24% |
| Shares Floating | 103.48M |
| Failed to Deliver (FTD) Shares | 169 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 12.7M, so 11.15% of the outstanding shares have been sold short.
| Short Interest | 12.7M |
| Short % of Shares Out | 11.15% |
| Short % of Float | 12.98% |
| Short Ratio (days to cover) | 3.69 |
Valuation Ratios
The PE ratio is -1.01 and the forward PE ratio is -0.8. Fate Therapeutics's PEG ratio is 0.
| PE Ratio | -1.01 |
| Forward PE | -0.8 |
| PS Ratio | 13.76 |
| Forward PS | 0.6 |
| PB Ratio | 0.59 |
| P/FCF Ratio | -1.52 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Fate Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.58, with a Debt / Equity ratio of 0.27.
| Current Ratio | 7.58 |
| Quick Ratio | 7.58 |
| Debt / Equity | 0.27 |
| Debt / EBITDA | -0.48 |
| Debt / FCF | -0.69 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $75.31K |
| Profits Per Employee | $-1.03M |
| Employee Count | 181 |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -88.53% in the last 52 weeks. The beta is 2.26, so Fate Therapeutics's price volatility has been higher than the market average.
| Beta | 2.26 |
| 52-Week Price Change | -88.53% |
| 50-Day Moving Average | 1.15 |
| 200-Day Moving Average | 2.62 |
| Relative Strength Index (RSI) | 31.71 |
| Average Volume (20 Days) | 2.28M |
Income Statement
In the last 12 months, Fate Therapeutics had revenue of 13.63M and earned -186.26M in profits. Earnings per share was -1.64.
| Revenue | 13.63M |
| Gross Profit | 13.63M |
| Operating Income | -210.28M |
| Net Income | -186.26M |
| EBITDA | -176.58M |
| EBIT | -195.54M |
| Earnings Per Share (EPS) | -1.64 |
Balance Sheet
The company has 36.06M in cash and 85.27M in debt, giving a net cash position of -49.21M.
| Cash & Cash Equivalents | 36.06M |
| Total Debt | 85.27M |
| Net Cash | -49.21M |
| Retained Earnings | -1.4B |
| Total Assets | 440.69M |
| Working Capital | 253.39M |
Cash Flow
In the last 12 months, operating cash flow was -122.87M and capital expenditures -730K, giving a free cash flow of -123.6M.
| Operating Cash Flow | -122.87M |
| Capital Expenditures | -730K |
| Free Cash Flow | -123.6M |
| FCF Per Share | -1.09 |
Margins
Gross margin is 100%, with operating and profit margins of -1542.63% and -1366.46%.
| Gross Margin | 100% |
| Operating Margin | -1542.63% |
| Pretax Margin | -1366.46% |
| Profit Margin | -1366.46% |
| EBITDA Margin | -1295.41% |
| EBIT Margin | -1542.63% |
| FCF Margin | -906.79% |
Dividends & Yields
FATE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for FATE is $5, which is 541% higher than the current price. The consensus rating is "Hold".
| Price Target | $5 |
| Price Target Difference | 541% |
| Analyst Consensus | Hold |
| Analyst Count | 8 |
Scores
| Altman Z-Score | -4.76 |
| Piotroski F-Score | 2 |